导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.29% | 3649/4773 |
| 近一周 | -1.62% | 2990/5467 |
| 近一月 | -3.88% | 1411/5421 |
| 近一季 | 0.33% | 950/5238 |
| 近半年 | -5.74% | 3174/4931 |
| 近一年 | -14.65% | 3663/4400 |
| 近两年 | 32.52% | 2169/2954 |
| 近三年 | 32.09% | 986/2253 |
| 成立以来 | 6.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.15% 4048/4961 |
-9.58% 3974/5312 |
- - |
- - |
| 2025 | 18.64% 2297/4813 |
13.90% 211/3635 |
3.45% 1006/4076 |
7.06% 3481/4524 |
-5.95% 3652/4813 |
| 2024 | 33.38% 74/3463 |
1.45% 879/2808 |
12.18% 21/3014 |
14.63% 1939/3129 |
2.24% 970/3463 |
| 2023 | -9.77% 1230/2656 |
1.14% 1633/2280 |
-0.63% 394/2385 |
-6.00% 1411/2515 |
-4.49% 1058/2655 |
| 2022 | -6.52% 129/2207 |
-9.15% 310/1919 |
8.77% 328/2016 |
-15.52% 1308/2113 |
11.98% 132/2208 |
| 2021 | -17.96% 1170/1822 |
3.94% 165/1255 |
-2.43% 1206/1330 |
-13.02% 1328/1466 |
-6.99% 1560/1822 |
| 2020 | -5.28% 967/1250 |
-12.10% 871/1028 |
3.09% 949/1067 |
-5.37% 1110/1164 |
10.46% 595/1184 |
| 2019 | 16.25% 685/1092 |
10.87% 712/754 |
-0.25% 243/804 |
-3.05% 723/850 |
8.43% 318/918 |
| 2018 | - - |
- - |
- - |
- - |
-7.53% 66/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 平安港股通恒生中国企业ETF VS. 长安沪深300非周期A(740101) |